Amicus Therapeutics Analyst Ratings
Amicus Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 32.04% | Morgan Stanley | $14 → $15 | Maintains | Equal-Weight |
| 10/10/2023 | 23.24% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 09/29/2023 | 67.25% | JP Morgan | $17 → $19 | Maintains | Overweight |
| 07/11/2023 | 32.04% | Morgan Stanley | $15 → $15 | Reiterates | Equal-Weight → Equal-Weight |
| 03/28/2023 | 49.65% | B of A Securities | $16 → $17 | Maintains | Buy |
| 03/02/2023 | 49.65% | UBS | $15 → $17 | Maintains | Buy |
| 03/02/2023 | -3.17% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2023 | 40.85% | BTIG | $14 → $16 | Maintains | Buy |
| 11/08/2022 | 32.04% | Morgan Stanley | $14 → $15 | Maintains | Equal-Weight |
| 09/09/2022 | 23.24% | Morgan Stanley | → $14 | Initiates Coverage On | → Equal-Weight |
| 02/24/2022 | 23.24% | SVB Leerink | $16 → $14 | Maintains | Outperform |
| 01/14/2022 | 40.85% | SVB Leerink | $12 → $16 | Upgrades | Market Perform → Outperform |
| 01/13/2022 | 32.04% | Cantor Fitzgerald | $16 → $15 | Maintains | Overweight |
| 11/15/2021 | 40.85% | Stifel | $12 → $16 | Upgrades | Hold → Buy |
| 09/30/2021 | 40.85% | JP Morgan | → $16 | Upgrades | Neutral → Overweight |
| 09/30/2021 | 5.63% | SVB Leerink | $13 → $12 | Maintains | Market Perform |
| 05/27/2021 | — | Needham | Initiates Coverage On | → Hold | |
| 05/21/2021 | 40.85% | UBS | → $16 | Initiates Coverage On | → Buy |
| 04/14/2021 | — | Cantor Fitzgerald | Upgrades | Neutral → Overweight | |
| 03/22/2021 | 14.44% | SVB Leerink | $15 → $13 | Maintains | Market Perform |
| 03/02/2021 | 14.44% | Stifel | → $13 | Initiates Coverage On | → Hold |
| 02/12/2021 | 49.65% | Cantor Fitzgerald | $30 → $17 | Downgrades | Overweight → Neutral |
| 02/12/2021 | 67.25% | JP Morgan | → $19 | Downgrades | Overweight → Neutral |
| 02/12/2021 | 32.04% | SVB Leerink | $30 → $15 | Downgrades | Outperform → Market Perform |
| 12/14/2020 | 164.08% | SVB Leerink | $24 → $30 | Maintains | Outperform |
| 11/11/2020 | 84.86% | Berenberg | → $21 | Initiates Coverage On | → Hold |
| 11/06/2020 | 111.27% | SVB Leerink | $19 → $24 | Maintains | Outperform |
| 08/11/2020 | 76.06% | Citigroup | $15 → $20 | Maintains | Buy |
| 06/17/2020 | 67.25% | BTIG | → $19 | Initiates Coverage On | → Buy |
| 02/04/2020 | 76.06% | Cantor Fitzgerald | $19 → $20 | Assumes | → Overweight |
| 04/05/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 01/30/2019 | 76.06% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 01/17/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 12/18/2018 | 58.45% | Guggenheim | → $18 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/09/2023 | 32.04% | 摩根士丹利 | 14 美元 → 15 美元 | 維護 | 等重 |
| 2023 年 10 月 10 日 | 23.24% | 摩根士丹利 | 15 美元 → 14 美元 | 維護 | 等重 |
| 09/29/2023 | 67.25% | 摩根大通 | 17 美元 → 19 美元 | 維護 | 超重 |
| 07/11/2023 | 32.04% | 摩根士丹利 | 15 美元 → 15 美元 | 重申 | 等重 → 等重 |
| 03/28/2023 | 49.65% | B of A 類證券 | 16 美元 → 17 美元 | 維護 | 購買 |
| 03/02/2023 | 49.65% | 瑞銀（UBS） | 15 美元 → 17 美元 | 維護 | 購買 |
| 03/02/2023 | -3.17% | 高盛 | 10 美元 → 11 美元 | 維護 | 中立 |
| 01/18/2023 | 40.85% | BTIG | 14 美元 → 16 美元 | 維護 | 購買 |
| 2022 年 8 月 11 日 | 32.04% | 摩根士丹利 | 14 美元 → 15 美元 | 維護 | 等重 |
| 09/09/2022 | 23.24% | 摩根士丹利 | → 14 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 2022 年 2 月 24 日 | 23.24% | SVB Leerink | 16 美元 → 14 美元 | 維護 | 跑贏大盤 |
| 2022 年 1 月 14 日 | 40.85% | SVB Leerink | 12 美元 → 16 美元 | 升級 | 市場表現 → 跑贏大盤 |
| 01/13/2022 | 32.04% | 坎託·菲茨傑拉德 | 16 美元 → 15 美元 | 維護 | 超重 |
| 11/15/2021 | 40.85% | Stifel | 12 美元 → 16 美元 | 升級 | 持有 → 買入 |
| 09/30/2021 | 40.85% | 摩根大通 | → 16 美元 | 升級 | 中性 → 增持 |
| 09/30/2021 | 5.63% | SVB Leerink | 13 美元 → 12 美元 | 維護 | 市場表現 |
| 05/27/2021 | — | 尼德姆 | 啓動覆蓋範圍開啓 | → 按住 | |
| 05/21/2021 | 40.85% | 瑞銀（UBS） | → 16 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 4 月 14 日 | — | 坎託·菲茨傑拉德 | 升級 | 中性 → 增持 | |
| 03/22/2021 | 14.44% | SVB Leerink | 15 美元 → 13 美元 | 維護 | 市場表現 |
| 2021 年 2 月 3 日 | 14.44% | Stifel | → 13 美元 | 啓動覆蓋範圍開啓 | → 按住 |
| 02/12/2021 | 49.65% | 坎託·菲茨傑拉德 | 30 美元 → 17 美元 | 降級 | 超重 → 中性 |
| 02/12/2021 | 67.25% | 摩根大通 | → 19 美元 | 降級 | 超重 → 中性 |
| 02/12/2021 | 32.04% | SVB Leerink | 30 美元 → 15 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 2020 年 12 月 14 日 | 164.08% | SVB Leerink | 24 美元 → 30 美元 | 維護 | 跑贏大盤 |
| 11/11/2020 | 84.86% | 貝倫貝格 | → 21 美元 | 啓動覆蓋範圍開啓 | → 按住 |
| 11/06/2020 | 111.27% | SVB Leerink | 19 美元 → 24 美元 | 維護 | 跑贏大盤 |
| 08/11/2020 | 76.06% | 花旗集團 | 15 美元 → 20 美元 | 維護 | 購買 |
| 2020 年 6 月 17 日 | 67.25% | BTIG | → 19 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 02/04/2020 | 76.06% | 坎託·菲茨傑拉德 | 19 美元 → 20 美元 | 假設 | → 超重 |
| 2019 年 5 月 4 日 | — | 詹尼蒙哥馬利斯科特 | 啓動覆蓋範圍開啓 | → 購買 | |
| 01/30/2019 | 76.06% | 坎託·菲茨傑拉德 | → 20 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 01/17/2019 | — | 花旗集團 | 升級 | 中性 → 買入 | |
| 12/18/2018 | 58.45% | 古根海姆 | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Amicus Therapeutics (FOLD)?
Amicus Therapeutics（FOLD）的目標價格是多少？
The latest price target for Amicus Therapeutics (NASDAQ: FOLD) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $15.00 expecting FOLD to rise to within 12 months (a possible 32.04% upside). 8 analyst firms have reported ratings in the last year.
摩根士丹利於2023年11月9日公佈了Amicus Therapeutics（納斯達克股票代碼：FOLD）的最新目標股價。該分析公司將目標股價設定爲15.00美元，預計FOLD將在12個月內上漲至15.00美元（可能上漲32.04％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Amicus Therapeutics (FOLD)?
Amicus Therapeutics（FOLD）的最新分析師評級是多少？
The latest analyst rating for Amicus Therapeutics (NASDAQ: FOLD) was provided by Morgan Stanley, and Amicus Therapeutics maintained their equal-weight rating.
Amicus Therapeutics（納斯達克股票代碼：FOLD）的最新分析師評級由摩根士丹利提供，Amicus Therapeutics維持同等權重評級。
When is the next analyst rating going to be posted or updated for Amicus Therapeutics (FOLD)?
Amicus Therapeutics（FOLD）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Amicus Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Amicus Therapeutics的最後一次評級是在2023年11月9日發佈的，因此您應該預計下一個評級將在2024年11月9日左右公佈。
Is the Analyst Rating Amicus Therapeutics (FOLD) correct?
分析師評級Amicus Therapeutics（FOLD）是否正確？
While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a maintained with a price target of $14.00 to $15.00. The current price Amicus Therapeutics (FOLD) is trading at is $11.36, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但Amicus Therapeutics（FOLD）的最新評級維持不變，目標股價爲14.00美元至15.00美元。Amicus Therapeutics（FOLD）目前的交易價格爲11.36美元，超出了分析師的預期區間。